8-KShareholder MattersCorporate ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Bylaw Amendment (May 10, 2010)

Filed May 10, 2010For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K report on May 10, 2010, detailing actions taken at their Annual Stockholders Meeting on May 4, 2010. The primary focus of this filing revolves around significant amendments to the company's Certificate of Incorporation and Bylaws, approved by stockholders. These changes aim to enhance corporate governance by allowing stockholders holding at least 25% of voting power to call special meetings and by eliminating a previously existing supermajority provision for common stockholders. Additionally, the Board of Directors amended the company's Bylaws to formally separate the roles of Chairman and CEO, and clarified that the Chairman and Vice Chairman are not company officers. The report also confirms the election of 11 directors and the ratification of Deloitte as the independent auditor for 2010. Notably, several stockholder proposals concerning executive compensation, action by written consent, and animal use reporting were rejected by the shareholders.

Key Highlights

  • 1Stockholders approved amendments to the Certificate of Incorporation allowing holders of at least 25% of voting power to call special meetings.
  • 2A supermajority voting requirement for common stockholders was eliminated, simplifying decision-making processes.
  • 3The Board of Directors amended Bylaws to formally separate the Chairman and CEO positions.
  • 4All 11 nominated directors were elected to serve until the 2011 Annual Meeting.
  • 5Deloitte was ratified as Bristol-Myers Squibb's independent registered public accounting firm for 2010.
  • 6Stockholder proposals regarding executive compensation disclosure, action by written consent, and animal use reporting were rejected.

Frequently Asked Questions

Stockholders approved two significant governance changes: first, an amendment allowing shareholders with at least 25% of the voting power to call special meetings, and second, the elimination of a supermajority voting requirement for common stockholders. These changes enhance shareholder rights and streamline corporate decision-making.

Yes, the Board of Directors amended the Bylaws to reflect the separation of the Chairman and Chief Executive Officer positions. It was also clarified that the Chairman and Vice Chairman of the Board are not considered officers of the company.

The appointment of Deloitte as Bristol-Myers Squibb's independent registered public accounting firm for the fiscal year 2010 was ratified by the stockholders with overwhelming support.

No, several stockholder proposals concerning executive compensation disclosure, action by written consent, and a report on animal use were presented, but all were rejected by the shareholders.